Where would you like to sign in?

Algeta ASA : Hilde Furberg and Paolo Pucci elected as new members of Algeta's Board of Directors

OSLO, NORWAY--(Marketwired - Apr 12, 2013) - Algeta ASA (OSE: ALGETA), a company focused on
the
development of novel targeted cancer therapeutics, is very pleased to
announce
that Mrs Hilde Furberg and Mr Paolo Pucci were elected as new Non-executive
members of its Board of Directors at the Company's annual general meeting
held
in Oslo on 11 April 2013.

Hilde Furberg (born 1958) has 30 years of experience in the
pharmaceutical
industry. She is currently Senior Vice President Rare Disease EMEA at
Genzyme
(Sanofi), which she joined in 2002. She opened the first operation for
Genzyme
in the Nordic region and has also had management responsibility for
Genzyme in
the BeneLux region. Prior to Genzyme, Mrs Furberg spent 15 years at
Baxter in
various business roles of increasing seniority. She is a Non-executive
Director
on the Board of Clavis Pharma ASA and is a board member of Copenhagen
Capacity.
Previous board memberships include Probi AB and Pronova Biopharma ASA
(until the
acquisition by BASF).

Mrs Furberg holds a Master of Science degree in Nuclear Analytical
Chemistry
from the University of Oslo. She is a Norwegian citizen and resides
in de
Naarden, Netherlands.

Mrs Furberg holds 200 shares and no options in Algeta ASA and she has not
worked
as a consultant for the Company.

Paolo Pucci (born 1961) is Chief Executive Officer and member of the
Board of
Directors of ArQule Inc., a US-based, Nasdaq-listed cancer therapeutics
company,
which he joined in 2008. Before this, Mr Pucci was at Bayer AG, where he
held
sequential responsibilities as Country Head Bayer Italy
Pharmaceuticals,
President & SVP Bayer Pharmaceuticals North America - Global
Specialty
Pharmaceuticals, and member of the Bayer Pharmaceuticals Executive
Committee. He
concluded his tenure at Bayer as President in charge of the Bayer-
Schering
Pharmaceuticals Global Oncology/Specialized Therapeutics Business Units
and was
instrumental in building Bayer's global oncology franchise for
Nexavar(®). Prior
to this, Mr Pucci held positions of increasing responsibility with Eli
Lilly
between 1992 and 2001, culminating with his appointment as Managing
Director,
Eli Lilly Sweden AB. Mr Pucci is Non-executive Director on the Board of
Dyax,
Inc.

Mr Pucci holds an MBA from the University of Chicago and is a graduate
of the
Universita Degli Studi Di Napoli in Naples, Italy. Mr Pucci is an
Italian
citizen and resides in Boston, MA, USA.

Mr Pucci holds no shares and no options in Algeta ASA and he has not worked
as a
consultant for the Company.

Stein Holst Annexstad, Algeta's Chairman, said: "We are very pleased to
welcome
Hilde and Paolo to the Algeta Board. Between them, they have a
wealth of
experience in the global pharma industry and particularly in the
clinical and
commercial development of innovative targeted cancer therapies. We look
forward
to the valuable contributions they will make to the further
growth and
development of Algeta. We would also like to thank Ingrid Wiik and Joe
Anderson,
who stepped down from the Board at the AGM, for their efforts and input
over
their respective periods with the Company."

About Algeta

Algeta is a company focused on developing novel targeted therapies for
patients
with cancer based on its alpha-pharmaceutical platform. The
Company is
headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC,
based in
Cambridge, MA performing commercial marketing operations in the US.
Algeta is
listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information
please
visit www.algeta.com.